ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 180 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2019. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $179,000 | -94.9% | 1,572 | -93.9% | 0.06% | -92.8% |
| Q4 2020 | $3,541,000 | -14.8% | 25,582 | -49.4% | 0.87% | -29.5% |
| Q3 2020 | $4,157,000 | +73.8% | 50,582 | +65.4% | 1.23% | +54.2% |
| Q2 2020 | $2,392,000 | +17.3% | 30,582 | -33.4% | 0.80% | -6.8% |
| Q1 2020 | $2,040,000 | +8.2% | 45,922 | +4.1% | 0.86% | +29.3% |
| Q4 2019 | $1,885,000 | +0.5% | 44,133 | 0.0% | 0.66% | -7.3% |
| Q3 2019 | $1,876,000 | -16.4% | 44,133 | +22.0% | 0.72% | -13.0% |
| Q2 2019 | $2,244,000 | +41.6% | 36,165 | -4.5% | 0.82% | +17.1% |
| Q1 2019 | $1,585,000 | 0.0% | 37,858 | 0.0% | 0.70% | +3.7% |
| Q4 2018 | $1,585,000 | -30.9% | 37,858 | +31.7% | 0.68% | -14.0% |
| Q3 2018 | $2,295,000 | +11.4% | 28,746 | +6.2% | 0.79% | +3.3% |
| Q2 2018 | $2,061,000 | +26.4% | 27,074 | -15.4% | 0.76% | +13.6% |
| Q1 2018 | $1,631,000 | – | 31,991 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |